Download US GAAP: Issues and Solutions for the Pharmaceuticals and Life Sciences Industries

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Capitalization and impairment
6. Development expenditure once capitalization criteria are met—Scenario 2
Background
Relevant guidance
Company A has developed a vaccine delivery device and is now
continuing expenditure on the device to add new functionality.
The additional functionality will require Company A to receive
regulatory approval prior to selling the device.
Research and development costs… shall be charged to expense
when incurred [ASC 730–10–25–1].
Expenses are outflows or other using up of assets or incurrences
of liabilities (or a combination of both) from delivering or
producing goods, rendering services, or carrying out other
activities that constitute the entity’s ongoing major or central
operations [CON 6, par. 80].
Should Company A capitalize these
development costs? 
Solution
No. Company A should expense as incurred the costs of adding new functionality as these costs are research and
development expenditures.
PwC
7